# Targeting Vascular Reactivity in Idiopathic Pulmonary Fibrosis

> **NCT00981747** · PHASE2,PHASE3 · TERMINATED · sponsor: **Alicia Gerke** · enrollment: 12 (actual)

## Conditions studied

- Idiopathic Pulmonary Fibrosis
- Pulmonary Fibrosis

## Interventions

- **DRUG:** Sildenafil
- **DRUG:** Losartan
- **DRUG:** Sildenafil and Losartan
- **DRUG:** Placebo Oral Tablet

## Key facts

- **NCT ID:** NCT00981747
- **Lead sponsor:** Alicia Gerke
- **Sponsor class:** OTHER
- **Phase:** PHASE2,PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2009-09
- **Primary completion:** 2016-12
- **Final completion:** 2016-12
- **Target enrollment:** 12 (ACTUAL)
- **Why stopped:** Funding was withdrawn.
- **Last updated:** 2018-11-13

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00981747

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00981747, "Targeting Vascular Reactivity in Idiopathic Pulmonary Fibrosis". Retrieved via AI Analytics 2026-07-02 from https://api.ai-analytics.org/clinical/NCT00981747. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*